How Does the Latest Clinical Pharmacology Data & Modeling Support Continued Lecanemab Dosing?
Larisa Reyderman, Brian A Willis, Natasha Penner, Arnaud Charil, Shobha Dhadda, Steven Hersch, Michael C Irizarry, Lynn D Kramer · 2025
Read How Does the Latest Clinical Pharmacology Data & Modeling Support Continued Lecanemab Dosing? by Larisa Reyderman, Brian A Willis, Natasha Penner, Arnaud Charil, Shobha Dhadda, Steven Hersch, Michael C Irizarry, Lynn D Kramer (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713026.txt.
Description
Larisa Reyderman and seven co-authors published a study in 2025 on why patients should keep taking the Alzheimer's antibody lecanemab beyond the first year and a half. Trials showed the drug clears amyloid and slows decline for up to thirty months so far, and a treatment gap in an earlier study hinted that stopping loses ground. The open question was whether spacing doses out later keeps the benefit.
The team pooled two large trials and built models linking drug exposure, brain amyloid scans, blood markers, and thinking scores. The models projected four years of outcomes under continued and reduced schedules. Simulated results supported ongoing maintenance dosing rather than a hard stop. Modeling of this kind helps regulators and doctors set a long-term rhythm for an expensive therapy.
Catalog record
| CREATOR | Larisa Reyderman, Brian A Willis, Natasha Penner, Arnaud Charil, Shobha Dhadda, Steven Hersch, Michael C Irizarry, Lynn D Kramer |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |